Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To compare the efficacy and safety of gemcitabine plus cisplatin (GP) and 5-fluorouracil plus cisplatin (PF) for metastatic nasopharyngeal carcinoma.
Methods: The clinical trials of GP and PF in the treatment of metastatic nasopharyngeal carcinoma (NPC) were searched in PubMed, EMBASE, Cochrane Library, and Web of Science. The literature search met the inclusion and exclusion criteria. The software Revman 5.4 was used for data analysis, and STATA 15.0 was used for publication bias.
Results: 10 studies were included in this meta-analysis. The results showed that the GP group had a higher clinical remission rate than the PF group (RR = 1.22, 95% CI (1.03-1.44), =0.02, =0.02). GP and PF groups in OS, PFS, and DMFS had the same effect at 1, 2, and 3 years (OS at 1 year: RR = 1.04, 95% CI (0.95-1.15), =0.37, =0.37; 2 years: RR = 1.08, 95% CI (0.94 1.23), =0.28, =0.28; 3 years: RR = 1.07, 95% CI (0.89 1.29), =0.46; PFS at 1 year: RR = 1.98, 95% CI (0.29 13.44), =0.49; 2 years: RR = 3.09, 95% CI (0.10 97.55), =0.52; 3 years: RR = 0.95, 95% CI (0.73 1.24), =0.71; DMFS at 1 year: RR = 1.01, 95% CI (0.90-1.14), =0.83; 3 years: RR = 1.10, 95% CI (0.85-1.41), =0.47. The number of hematological adverse reactions occurred in GP group was higher than the PF group.
Conclusion: The GP and PF groups had similar OS, PFS, and DMFS, but the GP group had a higher clinical remission rate. Therefore, GP may be the first choice for metastatic NPC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308559 | PMC |
| http://dx.doi.org/10.1155/2022/7233559 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era.
Eur J Cancer
September 2025
Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Aim Of The Study: The aim of the study is to describe clinical features, treatment approach and outcomes of recurrent/metastatic (R/M) NPC in non-endemic areas MATERIALS AND METHODS: This observational, retrospective and multicenter study was conducted within 36 referral hospital in non-endemic areas including Europe, Jordan, Kuwait, Turkey and United States of America. All NPC patients diagnosed between 2004 and 2016 and with a minimum 12 months of follow-up were included. Data entry started in January 2018 and closed in December 2023.
View Article and Find Full Text PDFCorrection: Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapy.
Front Oncol
August 2025
Radiation Oncology Center, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China.
[This corrects the article DOI: 10.3389/fonc.2025.
View Article and Find Full Text PDFShort-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013).
Front Immunol
September 2025
Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
While immunotherapy has demonstrated encouraging efficacy in locally advanced nasopharyngeal carcinoma (LANPC), the optimal combination modalities and treatment duration remain undetermined. In the present study, we developed a clinical trial protocol to evaluate shortened period of immunotherapy could enhance the efficacy of LANPC. This open-label, randomized, single-blind, multicenter phase II trial (Tori-013) investigates the efficacy and safety of toripalimab (anti-PD-1 monoclonal antibody) combined with induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in patients with stage III/IVa nasopharyngeal carcinoma (NPC).
View Article and Find Full Text PDFPhase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses.
Neuro Oncol
August 2025
Department of Neuro-Oncology. Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, US.
Background: Leptomeningeal disease (LMD) from solid tumors has a dismal prognosis, even following treatment with anti-PD-1 therapy. We performed a phase IB study evaluating the safety of Avelumab with whole brain radiotherapy (WBRT) in LMD (NCT03719768).
Methods: Fifteen patients were enrolled with LMD from breast, lung, nasopharyngeal, ovary, and pancreatic tumors.
Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer.
In Vivo
August 2025
Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Background/aim: This study aimed to explore the long-term outcomes of patients with recurrent/metastatic head and neck cancer (RM-HNC) treated with nivolumab in a real-world setting.
Patients And Methods: We retrospectively analyzed 53 patients with R/M-HNC treated with nivolumab between 2017 and 2024 at the Shinshu University Hospital. Clinical data included response rates, overall survival (OS), progression-free survival 1 (PFS1) 1, PFS2, and immune-related adverse events (irAEs).